Oliceridine injection, our lead product candidate, is a G protein-selective agonist at the mu‑opioid receptor being developed for the management of moderate to severe acute pain in hospitals or other controlled clinical settings where intravenous, or IV, opioid therapy is warranted.
Our pipeline includes several additional product candidates we have identified as potential best- or first-in-class therapies for a variety of critical unmet medical needs. These are all new molecules discovered by Trevena scientists using our proprietary platform.
May 10, 2019Trevena Reports First Quarter 2019 Results
Copyright © Trevena, Inc.